• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

in vivo

CRISPR Therapeutics
Biotech

CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit

CRISPR Tx reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310.
Nick Paul Taylor May 7, 2025 10:00am
Group of scientist or doctors and nurses wearing blue protective gloves putting their hands together

Novartis taps Vyriad’s viral vectors for in vivo T cell editing

Nov 20, 2024 12:00pm
world global globe ex-US country map regions

PharmaLegacy snaps up preclinical CRO

Sep 16, 2024 3:50pm
DNA gene therapy gene editing helix CRISPR

Sanofi, Scribe seal new in vivo collab worth more than $1.2B

Jul 17, 2023 11:30am
Image of a barcode being scanned

George Church-founded biotech tacks on $40M series A

Jul 14, 2022 8:00am
Novartis

Novartis pays $75M to form sickle cell in vivo gene editing pact

Jun 22, 2022 3:40am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings